ECSP17038599A - Composición farmacéutica para el tratamiento de enfermedades gastrointestinales - Google Patents

Composición farmacéutica para el tratamiento de enfermedades gastrointestinales

Info

Publication number
ECSP17038599A
ECSP17038599A ECIEPI201738599A ECPI201738599A ECSP17038599A EC SP17038599 A ECSP17038599 A EC SP17038599A EC IEPI201738599 A ECIEPI201738599 A EC IEPI201738599A EC PI201738599 A ECPI201738599 A EC PI201738599A EC SP17038599 A ECSP17038599 A EC SP17038599A
Authority
EC
Ecuador
Prior art keywords
treatment
pharmaceutical composition
gastrointestinal diseases
sucralfate
ranitidine
Prior art date
Application number
ECIEPI201738599A
Other languages
English (en)
Spanish (es)
Inventor
Sacher Eduard Sacher Gmbh Hotel
Jun Woo Lee
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17038599(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of ECSP17038599A publication Critical patent/ECSP17038599A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ECIEPI201738599A 2015-01-30 2017-06-20 Composición farmacéutica para el tratamiento de enfermedades gastrointestinales ECSP17038599A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30
KR1020150147513A KR101583452B1 (ko) 2015-01-30 2015-10-22 위장질환 치료용 의약 조성물

Publications (1)

Publication Number Publication Date
ECSP17038599A true ECSP17038599A (es) 2017-09-29

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201738599A ECSP17038599A (es) 2015-01-30 2017-06-20 Composición farmacéutica para el tratamiento de enfermedades gastrointestinales

Country Status (19)

Country Link
EP (1) EP3250199A4 (fr)
JP (1) JP6419347B2 (fr)
KR (2) KR101583452B1 (fr)
CN (1) CN107205947B (fr)
AR (1) AR105413A1 (fr)
CL (1) CL2017001680A1 (fr)
CO (1) CO2017006222A2 (fr)
EA (1) EA032385B9 (fr)
EC (1) ECSP17038599A (fr)
GE (2) GEP20196941B (fr)
MA (1) MA41432A (fr)
MX (1) MX375765B (fr)
MY (1) MY195824A (fr)
PE (1) PE20171340A1 (fr)
PH (1) PH12017550051A1 (fr)
SA (1) SA517382016B1 (fr)
TW (1) TWI635859B (fr)
UA (1) UA116517C2 (fr)
WO (1) WO2016122226A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (ko) 2017-10-11 2019-09-24 (주)휴럼 리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물
WO2019199134A1 (fr) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 Composition pharmaceutique comprenant du lénalidomide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3874917T2 (de) * 1987-03-09 1993-03-04 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (fr) * 1989-06-14 1991-01-30 Warner-Lambert Company Un modèle de structure de système craniomandibulaire humain
KR970006083B1 (ko) * 1992-01-22 1997-04-23 주식회사 대웅제약 위장질환 치료용 의약 조성물
ATE213635T1 (de) * 1994-04-26 2002-03-15 Chugai Pharmaceutical Co Ltd Verfahren für die herstellung schmelz-granulierte sucralfatzubereitung
JPH0879097A (ja) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd 携帯無線機
KR970006083A (ko) 1995-07-06 1997-02-19 한승준 자동차용 카울부의 와이어 고정장치 취부구조
JP2001513570A (ja) * 1997-08-25 2001-09-04 ザ、プロクター、エンド、ギャンブル、カンパニー 上部胃腸管不調治療用複合製剤
WO2000078307A1 (fr) * 1999-06-21 2000-12-28 Daewoong Pharmaceutical Co., Ltd. Preparation pharmaceutique a administration orale ayant une action therapeutique sur les troubles gastro-intestinaux, contenant de la ranitidine enrobee, du sous-citrate de bismuth et du sucralfate
JP2006076956A (ja) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk 胃炎の治療・予防用配合剤
KR101617054B1 (ko) * 2008-07-01 2016-04-29 라이온 가부시키가이샤 고형내복제제
KR20110105223A (ko) * 2010-03-18 2011-09-26 일양약품주식회사 일라프라졸 및 수크랄페이트와 비스무스 제제의 혼합물을 함유하는 위장질환을 예방 또는 치료하기 위한 경구용 약제 조성물
KR20140072673A (ko) * 2012-12-05 2014-06-13 (주)한국파비스제약 경구용 위장질환 치료를 위한 정제

Also Published As

Publication number Publication date
JP6419347B2 (ja) 2018-11-07
WO2016122226A2 (fr) 2016-08-04
EP3250199A4 (fr) 2018-08-08
MX2017007567A (es) 2017-10-19
KR20160094268A (ko) 2016-08-09
KR101583452B1 (ko) 2016-01-11
PE20171340A1 (es) 2017-09-13
PH12017550051A1 (en) 2018-01-29
CN107205947B (zh) 2020-05-22
GEAP201814551A (en) 2018-08-27
KR101583452B9 (ko) 2022-05-02
TW201639559A (zh) 2016-11-16
MA41432A (fr) 2017-12-05
EA201791458A1 (ru) 2017-11-30
GEP20186941B (en) 2019-01-10
WO2016122226A3 (fr) 2016-09-15
SA517382016B1 (ar) 2021-03-18
EA032385B1 (ru) 2019-05-31
CL2017001680A1 (es) 2018-01-12
CN107205947A (zh) 2017-09-26
JP2018503672A (ja) 2018-02-08
BR112017013857A2 (pt) 2018-02-27
AR105413A1 (es) 2017-10-04
CO2017006222A2 (es) 2017-09-20
TWI635859B (zh) 2018-09-21
MX375765B (es) 2025-03-07
UA116517C2 (uk) 2018-03-26
EA032385B9 (ru) 2019-07-31
EP3250199A2 (fr) 2017-12-06
GEP20196941B (en) 2019-01-10
MY195824A (en) 2023-02-22

Similar Documents

Publication Publication Date Title
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
MX394222B (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
UY37271A (es) Composiciones nasales de cannabinoides
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
MX376200B (es) Formulacion en polvo nasal para el tratamiento de hipoglicemia.
MX389178B (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
DK3168214T3 (da) Substituerede 2-thioxo-imidazolidin-4-oner og spiro- analoger deraf, aktiv anti-canceringrediens, farmaceutisk sammensætning, medicinpræparat, fremgangsmåde til behandling af prostatacancer
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
DOP2016000161A (es) Ureas asimétricas p- sustituidas y usos médicos de las mismas.
CO2017006222A2 (es) Composición farmacéutica para el tratamiento de enfermedades gastrointestinales
ZA201805408B (en) Medicament for treatment of diabetic foot infections
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
ITUB20169928A1 (it) Formulazioni farmaceutiche per il trattamento del diabete
GT201600190A (es) Compuestos químicos
MX390488B (es) Composicion farmaceutica de clorhidrato de amantadina-loratadina-paracetamol para integrar una capsula, para el tratamiento de refriados entre otras alopatias.
UY35989A (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria
CL2018001236A1 (es) Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo.
BR112017003900A2 (pt) formulações de testosterona e métodos de tratamento com as mesmas
BR112017018637A2 (pt) 2,4 diamino-quinolina substituída como novos agentes anticancerígenos